Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

Author:

Gouda M.A.,Subbiah V.

Funder

Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston

National Institutes of Health

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy

National Cancer Institute

Cancer Prevention and Research Institute of Texas

University of Texas MD Anderson Cancer Center

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference87 articles.

1. The RAF proteins take centre stage;Wellbrock;Nat Rev Mol Cell Biol,2004

2. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions;Pearson;Endocr Rev,2001

3. Clinical development of BRAF plus MEK inhibitor combinations;Subbiah;Trends Cancer,2020

4. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

5. AACR Project GENIE: Powering Precision Medicine through an International Consortium;Cancer Discov,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3